Moderna, Merck Report Positive Trial Results for mRNA Melanoma Vaccine

Moderna and Merck announced on August 19-20, 2026, that their experimental mRNA-based cancer treatment, known as intismeran, passed a key test in a clinical trial for melanoma, a form of skin cancer. The treatment is a personalized cancer vaccine designed to be tailored to individual patients based on the unique mutations found within their tumors. Following the announcement, shares of Moderna surged, with one report citing a 177% increase in stock value. The trial results showed that the treatment extended the length of time patients remained cancer-free after treatment, compared to those who did not receive it. The companies and some medical observers characterized the results as a significant development in melanoma treatment, with one description calling it a "landmark moment" for one of the deadliest forms of skin cancer. Moderna's shift toward cancer treatment research comes as the company's financial fortunes had previously declined due to falling demand for its COVID-19 vaccines, prompting increased investment in alternative therapeutic areas including oncology. It remains unclear exactly how long the cancer-free benefit from the treatment lasts, as this detail was not specified in available reporting. The treatment has not yet received regulatory approval, and no timeline for potential approval or wider availability was disclosed in the reports. Further details about the trial's methodology, patient population size, and long-term follow-up data were not addressed in the available coverage.